Rituximab for minimal change disease in adults: long-term follow-up | Zendy

Annette Bruchfeld | Zendy; Szabolcs Benedek | Zendy; Marie Hilderman | Zendy; C. Medin | Zendy; S. Snaedal-Jonsdottir | Zendy; Maarit Korkeila | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab for minimal change disease in adults: long-term follow-up

Author(s) -

Annette Bruchfeld,

Szabolcs Benedek,

Marie Hilderman,

C. Medin,

S. Snaedal-Jonsdottir,

Maarit Korkeila

Publication year - 2013

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gft312

Subject(s) - medicine , rituximab , minimal change disease , nephrotic syndrome , pediatrics , disease , nephropathy , glomerulonephritis , endocrinology , focal segmental glomerulosclerosis , kidney , diabetes mellitus , lymphoma

Minimal change nephropathy or disease (MCD) accounts for 10-15% of cases of the nephrotic syndrome in adults with frequent relapses occurring in up to 25% of cases. The drug of choice is glucocorticoids (GCs), but GC-dependence is seen in 25-30%. Treatment with rituximab has been found to be effective in relapsing and GC-dependent cases, but little data are available regarding long-term outcome in adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research